ERBB2 and breast carcinoma: A study evaluating the combination of T-DM1, lapatinib, and nab-paclitaxel in patients with metastatic HER2-overexpressing breast cancer reported that 12 patients (85.7%) achieved an objective response, including 6 complete responses (CR) and 2 partial responses (PR).